Table 1 Baseline characteristics in the training set and validation set
Variable | A-LMR ≥ 1 (N = 59) | A-LMR < 1 (N = 50) | p value |
|---|---|---|---|
At diagnosis | |||
Age, years, median (range) | 53 (18–71) | 56 (20–75) | 0.2 |
Gender | 0.2 | ||
Male | 38 (64 %) | 25 (50 %) | |
Female | 21 (36 %) | 25 (50 %) | |
LDH (U/L), median (range) | 211 (116–928) | 276.5 (137–1539) | 0.04 |
Extra-nodal site | 0.05 | ||
0 | 7 (12 %) | 6 (12 %) | |
1 | 49 (83 %) | 34 (68 %) | |
2 | 3 (5 %) | 10 (20 %) | |
B symptoms | 0.9 | ||
Yes | 17 (29 %) | 15 (30 %) | |
No | 42 (71 %) | 35 (70 %) | |
Stage | <0.001 | ||
I | 2 (3 %) | 1 (2 %) | |
II | 26 (44 %) | 5 (10 %) | |
III | 9 (15 %) | 12 (24 %) | |
IV | 22 (38 %) | 32 (64 %) | |
Bone marrow involvement | 0.5 | ||
Yes | 15 (25 %) | 16 (32 %) | |
No | 44 (75 %) | 34 (68 %) | |
Bulky disease | 0.8 | ||
Yes | 3 (5 %) | 6 (6 %) | |
No | 56 (95 %) | 47 (94 %) | |
Hemoglobin (g/dl), median (range) | 12.5 (8.1–13.1) | 12.5 (6.6–16.9) | 0.6 |
Platelets × 109/l, median (range) | 231 (14–626) | 214 (31–719) | 0.06 |
IPI score | 0.01 | ||
0 | 13 (22 %) | 2 (4 %) | |
1 | 19 (32 %) | 12 (24 %) | |
2 | 17 (29 %) | 18 (36 %) | |
3 | 8 (13 %) | 10 (20 %) | |
4 | 1 (2 %) | 7 (14 %) | |
5 | 1 (2 %) | 1 (2 %) | |
Performance status | 0.3 | ||
0 | 7 (12 %) | 4 (8 %) | |
1 | 45 (76 %) | 43 (86 %) | |
2 | 5 (8 %) | 3 (6 %) | |
3 | 2 (45 %) | 0 (0 %) | |
T-cell lymphoma histologies | 0.9 | ||
Anaplastic large cell | 10 (17 %) | 5 (13 %) | |
Angioimmunoblastic | 15 (25 %) | 15 (27 %) | |
Enteropathy-associated | 6 (10 %) | 3 (6 %) | |
Hepatosplenic | 1 (2 %) | 1 (2 %) | |
NK/T | 7 (12 %) | 6 (12 %) | |
Panniculitis | 4 (7 %) | 3 (6 %) | |
Peripheral | 16 (27 %) | 17 (34 %) | |
IPI factors | |||
Age, years | 0.3 | ||
60 | 18 (31 %) | 20 (40 %) | |
≤60 | 41 (69 %) | 30 (60 %) | |
LDH (U/L) | 0.03 | ||
Normal | 34 (58 %) | 18 (36 %) | |
Abnormal | 25 (42 %) | 32 (64 %) | |
Performance status | 0.3 | ||
1 | 7 (12 %) | 3 (6 %) | |
≤1 | 52 (88 %) | 47 (94 %) | |
Extra-nodal disease | 0.02 | ||
1 | 3 (5 %) | 10 (20 %) | |
≤1 | 56 (95 %) | 40 (80 %) | |
Stage | <0.001 | ||
I/II | 28 (47 %) | 6 (12 %) | |
III/IV | 31 (53 %) | 44 (88 %) | |
IPI index | 0.03 | ||
2 | 10 (17 %) | 18 (36 %) | |
≤2 | 49 (83 %) | 32 (64 %) | |
Initial chemotherapy | 0.9 | ||
CHOP | 58 (98 %) | 49 (98 %) | |
SMILE | 1 (2 %) | 1 (2 %) | |
Salvage chemotherapy (N = 51) | 0.2 | ||
CDE | 2 (9 %) | 0 (0 %) | |
DHAP | 5 (21 %) | 8 (29 %) | |
ICE | 16 (70 %) | 20 (71 %) | |
Up-front transplant | 0.09 | ||
Yes | 36 (61 %) | 22 (44 %) | |
No | 23 (39 %) | 28 (56 %) | |
At transplant | |||
Pre-transplant clinical status | <0.001 | ||
CR | 51 (86 %) | 25 (50 %) | |
PR | 8 (15 %) | 25 (50 %) | |
Plerixafor | 0.8 | ||
Yes | 21 (36 %) | 19 (38 %) | |
No | 38 (64 %) | 31 (62 %) | |
Infused CD34, median (range) | 5.42 (2.25–13.44) | 5.12 (2.04–15.65) | 0.9 |
Number of collections | 0.08 | ||
1 | 7 (12 %) | 12 (24 %) | |
2 | 19 (32 %) | 15 (30 %) | |
3 | 19 (32 %) | 9 (18 %) | |
4 | 7 (12 %) | 11 (22 %) | |
5 | 1 (2 %) | 2 (4 %) | |
6 | 3 (5 %) | 0 (0 %) | |
7 | 2 (3 %) | 0 (0 %) | |
8 | 1 (2 %) | 1 (2 %) | |
A-ALC, median (range) | 0.68 (0.21–3.83) | 0.44 (0.06–1.40) | <0.001 |
A-AMC, median (range) | 0.45 (0.10–1.42) | 0.78 (0.20–1.60) | <0.001 |
ALC-15, median (range) | 0.71 (0.10–2.31) | 0.41 (0.10–1.18) | <0.001 |
AMC-15, median (range) | 0.43 (0.04–1.19) | 0.90 (0.20–2.31) | <0.001 |
LMR-15 | 1.71 (0.24–15.5) | 0.57 (0.08–3.18) | <0.001 |